RxDoctor Payments Data

Regina Soderberg

Family · Bradenton, FLNPI 1508151838

Payments from drug & device makers

$1,156in general payments, 2019–2025

Across 11 payments — averaging $105.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$236
  • Axsome Therapeutics, Inc.$124
  • Pulmonx Corporation$110
  • MDD US Operations, LLC$107
  • Abiomed$107
  • Abbott$105
  • plus $367 from 4 others

What the payments were for

  • Food & beverage$1,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,156 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$272,490
Medicare patients
177
Services billed
2,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$80,988
JardianceEmpagliflozin43$25,613
MyrbetriqMirabegron49$21,385
XareltoRivaroxaban38$20,405
JanuviaSitagliptin Phosphate22$13,881
Breo ElliptaFluticasone/Vilanterol30$12,897
TrintellixVortioxetine Hydrobromide13$6,329
FarxigaDapagliflozin Propanediol11$6,197
Pantoprazole Sodium223$5,720
Levothyroxine Sodium387$5,011
Gabapentin132$4,323
Atorvastatin Calcium263$3,797
Losartan Potassium166$3,521
Metoprolol Succinate155$2,954
CholestyramineCholestyramine (With Sugar)28$2,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$102$25,61343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →